Kamada Ltd. (KMDA)Healthcare | Drug Manufacturers - Specialty & Generic | Rehovot, Israel | NasdaqGS
8.49 USD
+0.25
(3.034%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 8.49 Short-term: ★★☆☆☆ | Long-term: ★★★☆☆ | Dividends: ★★★★☆ |
Hot Take | April 11, 2026, 3:01 p.m. EDT
Kamada Ltd. (KMDA) presents a mixed picture for short-term and long-term investors. The recent price action has been relatively stable, with a slight dip from the 52-week high, but the stock remains above the 52-week low. The dividend yield is attractive at 2.94%, and the company has a history of paying dividends, which supports a moderate long-term rating. However, the stock's fundamentals show mixed signals, with declining earnings growth and a high debt-to-equity ratio. Short-term traders might consider the recent dip as a buying opportunity, but long-term investors should be cautious due to the company's financial leverage and uncertain earnings outlook. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.030450 |
| AutoETS | 0.032417 |
| AutoARIMA | 0.032782 |
| AutoTheta | 0.038927 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.31 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.799 |
| Excess Kurtosis | -0.39 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Ex Dividend Date | 2026-03-22 |
| Last Dividend Date | 2026-03-22 |
| Debt to Equity Ratio | 4.297 |
| Revenue per Share | 3.13 |
| Market Cap | 490,857,920 |
| Trailing P/E | 24.26 |
| Forward P/E | 14.31 |
| Beta | 0.31 |
| Profit Margins | 11.19% |
| Website | https://www.kamada.com |
As of April 11, 2026, 3:01 p.m. EDT: Options speculators are showing mixed signals. For near-term expirations, there is a concentration of open interest and volume around the $7.5 strike, indicating some short-term support. However, the higher strike prices like $10.0 and $15.0 show limited interest, suggesting limited upside speculation. The low implied volatility for longer-dated options might indicate a lack of conviction in significant price movements. Overall, the options activity suggests cautious optimism with limited directional bias.
| Last Yield | 1yr Yield | 3yr Avg | 5yr Avg |
|---|---|---|---|
| 3.05% | 3.05% | 2.03% | 1.22% |
| Date | Dividend | Yield % |
|---|---|---|
| 2026-03-23 | 0.250 | 3.048781 |
| 2025-03-17 | 0.200 | 3.030303 |
| 2013-06-13 | 0.006 | 0.060332 |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.28750002 |
| Address1 | 2 Holzman Street |
| Address2 | Science Park PO Box 4081 |
| All Time High | 17.95 |
| All Time Low | 3.02 |
| Ask | 10.84 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 32,270 |
| Average Daily Volume3 Month | 70,834 |
| Average Volume | 70,834 |
| Average Volume10Days | 32,270 |
| Beta | 0.309 |
| Bid | 6.05 |
| Bid Size | 2 |
| Book Value | 4.664 |
| City | Rehovot |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.49 |
| Current Ratio | 4.074 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 8.57 |
| Day Low | 8.39 |
| Debt To Equity | 4.297 |
| Display Name | Kamada |
| Dividend Date | 1,775,520,000 |
| Dividend Rate | 0.25 |
| Dividend Yield | 2.94 |
| Earnings Call Timestamp End | 1,773,232,200 |
| Earnings Call Timestamp Start | 1,773,232,200 |
| Earnings Growth | -0.141 |
| Earnings Quarterly Growth | -0.065 |
| Earnings Timestamp | 1,773,232,200 |
| Earnings Timestamp End | 1,778,675,400 |
| Earnings Timestamp Start | 1,778,675,400 |
| Ebitda | 39,512,000 |
| Ebitda Margins | 0.21895 |
| Enterprise To Ebitda | 10.778 |
| Enterprise To Revenue | 2.36 |
| Enterprise Value | 425,846,624 |
| Eps Current Year | 0.505 |
| Eps Forward | 0.59333 |
| Eps Trailing Twelve Months | 0.35 |
| Esg Populated | 0 |
| Ex Dividend Date | 1,774,224,000 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 972 8 940 6473 |
| Fifty Day Average | 8.5852 |
| Fifty Day Average Change | -0.09520054 |
| Fifty Day Average Change Percent | -0.011088913 |
| Fifty Two Week Change Percent | 28.750002 |
| Fifty Two Week High | 9.35 |
| Fifty Two Week High Change | -0.8600006 |
| Fifty Two Week High Change Percent | -0.09197867 |
| Fifty Two Week Low | 6.35 |
| Fifty Two Week Low Change | 2.1399999 |
| Fifty Two Week Low Change Percent | 0.33700785 |
| Fifty Two Week Range | 6.35 - 9.35 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,370,007,000,000 |
| Float Shares | 10,821,327 |
| Forward Eps | 0.59333 |
| Forward P E | 14.309068 |
| Free Cashflow | 7,593,625 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 462 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.4234 |
| Gross Profits | 76,407,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.07195 |
| Held Percent Institutions | 0.48948002 |
| Implied Shares Outstanding | 57,816,013 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Dividend Date | 1,774,224,000 |
| Last Dividend Value | 0.25 |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel. |
| Long Name | Kamada Ltd. |
| Market | us_market |
| Market Cap | 490,857,920 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_9002466 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | 20,198,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 477,993,496 |
| Number Of Analyst Opinions | 4 |
| Open | 8.39 |
| Operating Cashflow | 25,490,000 |
| Operating Margins | 0.07948 |
| Payout Ratio | 0.0 |
| Peg Ratio | 0.6 |
| Phone | 972 8 940 6472 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 8.49 |
| Post Market Time | 1,776,456,605 |
| Previous Close | 8.24 |
| Price Eps Current Year | 16.81188 |
| Price Hint | 2 |
| Price To Book | 1.8203259 |
| Price To Sales Trailing12 Months | 2.7200372 |
| Profit Margins | 0.11193 |
| Quick Ratio | 2.196 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.25 |
| Regular Market Change Percent | 3.03398 |
| Regular Market Day High | 8.57 |
| Regular Market Day Low | 8.39 |
| Regular Market Day Range | 8.39 - 8.57 |
| Regular Market Open | 8.39 |
| Regular Market Previous Close | 8.24 |
| Regular Market Price | 8.49 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 47,416 |
| Return On Assets | 0.043670002 |
| Return On Equity | 0.07643 |
| Revenue Growth | 0.145 |
| Revenue Per Share | 3.13 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 57,686,056 |
| Shares Percent Shares Out | 0.0028 |
| Shares Short | 162,767 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 136,757 |
| Short Name | Kamada Ltd. |
| Short Percent Of Float | 0.0052 |
| Short Ratio | 1.96 |
| Source Interval | 15 |
| Symbol | KMDA |
| Target High Price | 15.0 |
| Target Low Price | 11.0 |
| Target Mean Price | 13.0 |
| Target Median Price | 13.0 |
| Total Cash | 75,469,000 |
| Total Cash Per Share | 1.308 |
| Total Debt | 11,561,000 |
| Total Revenue | 180,460,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.25 |
| Trailing Annual Dividend Yield | 0.030339807 |
| Trailing Eps | 0.35 |
| Trailing P E | 24.257143 |
| Trailing Peg Ratio | 0.5975 |
| Triggerable | 1 |
| Two Hundred Day Average | 7.56995 |
| Two Hundred Day Average Change | 0.92004967 |
| Two Hundred Day Average Change Percent | 0.12153973 |
| Type Disp | Equity |
| Volume | 47,416 |
| Website | https://www.kamada.com |
| Zip | 7,670,402 |